ABSTRACT
The first choice of treatment for American cutaneous leishmaniasis is the pentavalent antimonial drug. Although it has been shown that this treatment is mostly effective and indicated, some disadvantages should be taken into account such as side effects, long term treatment inconveniences and counter-indication for patients suffering from cardiopathy, nephropathy; yet, aging, pregnancy and other conditions. With the advent of the vaccine anti-American cutaneous leishmaniasis as a prophylactic measure, studies on therapy using the vaccine associated or not with other drugs have been performed by many investigators and it is currently among the alternative treatments and prevention measures for American cutaneous leishmaniasis. In conclusion, the association between antimony and vaccine (immunochemotherapy) showed the same cure rate when compared with the standard treatment (100%) and it was also able to reduce the salt volume in 17.9% and treatment length from 87 to 62 days, decreasing side effects.
Subject(s)
Immunotherapy/methods , Leishmaniasis, Cutaneous/therapy , Adolescent , Adult , Aged , Aged, 80 and over , Animals , Antiprotozoal Agents/administration & dosage , BCG Vaccine/administration & dosage , Child , Child, Preschool , Drug Therapy, Combination , Female , Humans , Leishmania/immunology , Leishmaniasis, Cutaneous/immunology , Male , Meglumine/administration & dosage , Meglumine Antimoniate , Middle Aged , Organometallic Compounds/administration & dosage , Protozoan Vaccines/administration & dosage , Time Factors , Treatment OutcomeABSTRACT
O tratamento de primeira escolha para leishmaniose tegumentar americana é o antimonial pentavalente. Embora este tratamento seja na maioria das vezes efetivo e indicado, devem ser consideradas as desvantagens tais como efeitos colaterais, longa duracão do tratamento e contra-indicacão para cardiopatas, nefropatas, idosos, grávidas e outras condicões. Com o advento da vacina antileishmaniose tegumentar americana para fins profiláticos e terapêuticos, associando-a ou não a outros fármacos, muitas pesquisas têm sido desenvolvidas, sendo a vacina a principal entre os atuais recursos no tratamento e prevencão da leishmaniose tegumentar americana. Em conclusão, a associacão do antimônio com a vacina (imunoquimioterapia) apresentou o mesmo índice de cura em relacão ao tratamento padrão (100%), e ainda reduziu o volume do sal em 17,9% e o tempo de cura significativamente, de 87 para 62 dias; conseqüentemente, reduzindo os efeitos colaterais.
Subject(s)
Child, Preschool , Child , Adolescent , Adult , Middle Aged , Aged, 80 and over , Animals , Humans , Male , Female , Antiprotozoal Agents/administration & dosage , BCG Vaccine/administration & dosage , Leishmania/immunology , Leishmaniasis, Cutaneous/immunology , Leishmaniasis, Cutaneous/therapy , Meglumine/administration & dosage , Organometallic Compounds/administration & dosage , Protozoan Vaccines/administration & dosage , Drug Therapy, Combination , Time Factors , Treatment OutcomeABSTRACT
Previous work in our laboratory, mainly foccused the prospects of achieving resistance against Schistosoma mansoni infection with adult worm-derived antigens in the form of a soluble extract (SE). This extract obtained by incubation of living adult schistosomes in saline, contains a large number of distinct molecules and was actually shown to be a significantly protective in different outbred animals models such as Swiss mice and rabbits. It thus appeared worthwile to investigate the potencial protective activity of SE in different inbred strains of mice, known to be highly susceptible to the infection. Herein we present data showing that DBA/2 mice, once immunized with SE acquire significant levels of resistance to a S. mansoni cercarial challenge. In addition, preliminary studies on the immune system of immunized animals reveled that, injection of SE caused no general inbalance of B or T cell responses
Subject(s)
Animals , Muridae/parasitology , Schistosoma mansoni/pathogenicity , VaccinesABSTRACT
Foi realizado o tratamento de 62 pacientes portadores de leishmaniose tegumentar utilizando como agente imunoterápico uma vacina constituída de promastigotas mortas. O esquema terapêutico utilizado mostrou ser uma alternativa adequada ao tratamento de leishmaniose tegumentar já que houve sucesso terapêutico em 75,8% dos casos, näo se observando efeitos colaterais. A eficiência terapêutica foi semelhante nos casos de lesöes cutâneas ou mucosas
